Optimal intensity of oral anticoagulant therapy after myocardial infarction

Thoraxcenter, Department of Cardiology, University Hospital Dijkzigt, Erasmus University of Rotterdam, The Netherlands.

OBJECTIVES: This study attempted to determine the optimal intensity of anticoagulant therapy in patients after myocardial infarction. BACKGROUND: Treatment with oral anticoagulant therapy entails a delicate balance between over- (risk of bleeding) and under-anticoagulation (risk of thromboemboli). The optimal intensity required to prevent the occurrence of either event (bleeding or thromboembolic) is not known. METHODS: A method was used to determine the optimal intensity of anticoagulant therapy by calculating incidence rates for either event associated with a specific international normalized ratio. The numerator included events occurring at given international normalized ratios, and the denominator comprised the total observation time. RESULTS: The study population included 3,404 myocardial infarction patients enrolled in the ASPECT (Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis) trial. Total treatment was 6,918 patient-years. Major bleeding occurred in 57 patients (0.8/100 patient-years), and thromboembolic complications in 397 (5.7/100 patient-years). The incidence of the combined outcome (bleeding or thromboembolic complications) with international normalized ratio <2 was 8.0/100 patient-years (283 events in 3,559 patient-years), with international normalized ratios between 2 and 3, 3.9/100 patient-years (33 events in 838 patient-years); 3.2/100 patient-years (57 events in 1,775 patient-years) for international normalized ratios between 3 and 4; 6.6/100 patient-years (37 events in 564 patient-years) for international normalized ratios between 4 and 5; and 7.7/100 patient-years (14 events in 182 patient-years) for international normalized ratios >5. After adjustment for achieved international normalized ratio levels, significant predictors were higher levels of systolic blood pressure and age. CONCLUSIONS: If equal weight is given to hemorrhagic and thromboembolic complications, these results suggest that the optimal intensity of long-term anticoagulant therapy for myocardial infarction patients lies between 2.0 and 4.0 international normalized ratio, with a trend to suggest an optimal intensity of 3.0 to 4.0.

This article has been cited by other articles:

				D. Sibbing, S. R. Steinhubl, S. Schulz, A. Schomig, and A. Kastrati Platelet Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated Patients: Initial Evidence of a Therapeutic Window J. Am. Coll. Cardiol., July 20, 2010; 56(4): 317 - 318. [Full Text] [PDF]

				M. Torn, S. C. Cannegieter, W. L. E. M. Bollen, F. J. M. van der Meer, E. E. van der Wall, and F. R. Rosendaal Optimal Level of Oral Anticoagulant Therapy for the Prevention of Arterial Thrombosis in Patients With Mechanical Heart Valve Prostheses, Atrial Fibrillation, or Myocardial Infarction: A Prospective Study of 4202 Patients Arch Intern Med, July 13, 2009; 169(13): 1203 - 1209. [Abstract] [Full Text] [PDF]

				N. Oake MSc, A. Jennings MA, A. J. Forster MD MSc, D. Fergusson PhD, S. Doucette MSc, and C. van Walraven MD MSc Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis Can. Med. Assoc. J., July 29, 2008; 179(3): 235 - 244. [Abstract] [Full Text] [PDF]

				M. Levi, G. K. Hovingh, S. C. Cannegieter, M. Vermeulen, H. R. Buller, and F. R. Rosendaal Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based Blood, May 1, 2008; 111(9): 4471 - 4476. [Abstract] [Full Text] [PDF]

				C. van Walraven, N. Oake, P. S. Wells, and A. J. Forster Burden of Potentially Avoidable Anticoagulant-Associated Hemorrhagic and Thromobembolic Events in the Elderly Chest, May 1, 2007; 131(5): 1508 - 1515. [Abstract] [Full Text] [PDF]

				M. Torn, F. J. M. van der Meer, and F. R. Rosendaal Lowering the Intensity of Oral Anticoagulant Therapy: Effects on the Risk of Hemorrhage and Thromboembolism Arch Intern Med, March 22, 2004; 164(6): 668 - 673. [Abstract] [Full Text] [PDF]

				M. Torn, A. Algra, and F.R. Rosendaal Oral anticoagulation for cerebral ischemia of arterial origin: High initial bleeding risk Neurology, December 11, 2001; 57(11): 1993 - 1999. [Abstract] [Full Text] [PDF]

				H. I. Bussey Managing Excessive Warfarin Anticoagulation Ann Intern Med, September 18, 2001; 135(6): 460 - 462. [Full Text] [PDF]

				J. M. t. Berg, B. A. Hutten, J. C. Kelder, F. W. A. Verheugt, and H. W. T. Plokker Oral Anticoagulant Therapy During and After Coronary Angioplasty : The Intensity and Duration of Anticoagulation Are Essential to Reduce Thrombotic Complications Circulation, April 24, 2001; 103(16): 2042 - 2047. [Abstract] [Full Text] [PDF]

				R. Altman, J. Rouvier, and A. Scazziota State-of-the-Art Review : Secondary Prevention of Myocardial Infarction: Beneficial Effect of Combining Oral Anticoagulant Plus Aspirin: Therapy Based on Evidence Clinical and Applied Thrombosis/Hemostasis, July 1, 2000; 6(3): 126 - 134. [PDF]

				A. M. Whitling, H. I. Bussey, and R. M. Lyons Comparing Different Routes and Doses of Phytonadione for Reversing Excessive Anticoagulation Arch Intern Med, October 26, 1998; 158(19): 2136 - 2140. [Abstract] [Full Text] [PDF]

				E. Chiquette, M. G. Amato, and H. I. Bussey Comparison of an Anticoagulation Clinic With Usual Medical Care: Anticoagulation Control, Patient Outcomes, and Health Care Costs Arch Intern Med, August 10, 1998; 158(15): 1641 - 1647. [Abstract] [Full Text]

				R. Altman Controversies in Antithrombotic Therapy in Cardiovascular Diseases Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 11 - 24. [Abstract] [PDF]